The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer : a meta-analysis

• Published in: European journal of clinical pharmacology Vol. 51; no. 5; pp. 389 - 393
• Main Authors: CHRISTENSEN, P. M, GØTZSCHE, P. C, BRØSEN, K
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer 1997; Berlin
• Subjects: Biological and medical sciences; Cytochrome P-450 CYP2D6 - genetics; Cytochrome P-450 CYP2D6 - metabolism; Debrisoquin - metabolism; Disease Susceptibility; Genotype; Humans; Lung Neoplasms - etiology; Lung Neoplasms - genetics; Medical sciences; Odds Ratio; Oxidation-Reduction; Phenotype; Pneumology; Polymorphism, Genetic; Risk Factors; Sparteine - metabolism; Tumors of the respiratory system and mediastinum; Lung disease; Pharmacogenetics; Respiratory disease; Isozyme; Cytochrome P450; Debrisoquine; Sparteine; Malignant tumor; Metabolism; Bronchopulmonary; Amidine; Association; Risk factor; Bronchus disease; Hydroxylator phenotype; Oxidation
• ISSN: 0031-6970; 1432-1041
• DOI: 10.1007/s002280050219

To examine the association between the sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer. Meta-analysis of case-control studies using a random effects model. The "Main outcome measure" was the odds ratio for the risk of lung cancer, using extensive metabolisers as the reference group. Thirteen studies were identified. The studies were too heterogeneous to be pooled the size of the odds ratio increased with the sample size. When the analysis was restricted to the largest studies, there was no difference in risk between poor and extensive metabolisers (odds ratio 0.95, 95% confidence interval 0.68-1.33). No association was found between the CYP2D6 oxidation polymorphism and lung cancer risk when sample size bias was taken into account.